Literature DB >> 25204411

Prognostic significance of Ki-67 antigen expression in extranodal natural killer/T-cell lymphoma, nasal type.

Li Jiang1, Pengfei Li, Hua Wang, Jun Liu, Xinke Zhang, Huijuan Qiu, Bei Zhang.   

Abstract

Extranodal natural killer (NK)/T-cell lymphoma, nasal-type (ENKTL) is a clinically heterogeneous disease with poor prognosis and requires risk stratification in affected patients. Recent studies have shown that Ki-67 may serve as a prognostic marker in certain types of lymphoma. We analyzed Ki-67 expression and its correlation with prognosis in 182 patients with ENKTL from January 2002 to June 2013. The patients were classified into two groups through a median value: low (<60%) versus high Ki-67 (≥60%). High Ki-67 expression was more common in patients with B symptoms (p=0.02), bulky disease (p=0.001), and extraupper aerodigestive tract NK/T-cell lymphoma (p=0.001). High Ki-67 expression was significantly associated with poor overall survival (p<0.0001) and progression-free survival (p<0.0001). For patients with low-risk IPI or KPI, Ki-67 at diagnosis could contribute to distinguish patients with favorable outcomes from those with poor outcomes. The results of multivariate analysis showed that the high Ki-67 expression is an independent prognostic factor for overall survival and progression-free survival. (OS, p=0.001; PFS, p=0.003). Our data showed that Ki-67 is an effective prognostic indicator of survival in ENKTL patients. This prognostic index may be helpful in identifying high-risk patients with ENKTL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25204411     DOI: 10.1007/s12032-014-0218-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  28 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

Review 2.  Extranodal NK / T-cell lymphoma, nasal type: new staging system and treatment strategies.

Authors:  Tae Min Kim; Dae Seog Heo
Journal:  Cancer Sci       Date:  2009-08-19       Impact factor: 6.716

3.  Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients.

Authors:  A Avilés; N R Díaz; N Neri; S Cleto; A Talavera
Journal:  Clin Lab Haematol       Date:  2000-08

4.  A novel prognostic model for extranodal natural killer/T-cell lymphoma.

Authors:  Jia-Jia Huang; Ying-Jie Zhu; Yi Xia; Wei Zhao; Tong-Yu Lin; Wen-Qi Jiang; Hui-Qiang Huang; Zhi-Ming Li
Journal:  Med Oncol       Date:  2011-07-23       Impact factor: 3.064

5.  Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.

Authors:  M Jerkeman; H Anderson; M Dictor; S Kvaløy; M Akerman; E Cavallin-Ståhl
Journal:  Ann Hematol       Date:  2004-04-14       Impact factor: 3.673

6.  Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index.

Authors:  Chor-Sang Chim; Shing-Yan Ma; Wing-Yan Au; Carolyn Choy; Albert K W Lie; Raymond Liang; Chun-Chung Yau; Yok-Lam Kwong
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

7.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

8.  Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type.

Authors:  R Suzuki; J Suzumiya; M Yamaguchi; S Nakamura; J Kameoka; H Kojima; M Abe; T Kinoshita; T Yoshino; K Iwatsuki; Y Kagami; T Tsuzuki; M Kurokawa; K Ito; K Kawa; K Oshimi
Journal:  Ann Oncol       Date:  2009-10-22       Impact factor: 32.976

9.  Prognostic significance of Ki-67 antigen expression in non-Hodgkin's lymphomas.

Authors:  Katarzyna Szczuraszek; Grzegorz Mazur; Michał Jeleń; Piotr Dziegiel; Paweł Surowiak; Maciej Zabel
Journal:  Anticancer Res       Date:  2008 Mar-Apr       Impact factor: 2.480

10.  Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis.

Authors:  Xin He; Zhigang Chen; Tao Fu; Xueli Jin; Teng Yu; Yun Liang; Xiaoying Zhao; Liansheng Huang
Journal:  BMC Cancer       Date:  2014-03-05       Impact factor: 4.430

View more
  4 in total

1.  Predictors of survival of natural killer/T-cell lymphoma, nasal type, in a non-Asian population: a single cancer centre experience.

Authors:  Jule Vásquez; Mariana Serrano; Lourdes Lopez; Cristian Pacheco; Shirley Quintana
Journal:  Ecancermedicalscience       Date:  2016-11-02

2.  A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China.

Authors:  Rong Liang; Guang-Xun Gao; Jie-Ping Chen; Ji-Shi Wang; Xiao-Min Wang; Yun Zeng; Qing-Xian Bai; Tao Zhang; Lan Yang; Bao-Xia Dong; Hong-Tao Gu; Mi-Mi Shu; Cai-Xia Hao; Jian-Hong Wang; Na Zhang; Xie-Qun Chen
Journal:  Hematol Oncol       Date:  2016-10-10       Impact factor: 5.271

3.  Nomograms based on SUVmax of 18F-FDG PET/CT and clinical parameters for predicting progression-free and overall survival in patients with newly diagnosed extranodal natural killer/T-cell lymphoma.

Authors:  Hongyan Li; Guozhu Shao; Yajing Zhang; Xiaomin Chen; Chengcheng Du; Kun Wang; Zairong Gao
Journal:  Cancer Imaging       Date:  2021-01-08       Impact factor: 3.909

4.  Histological vascular invasion is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type.

Authors:  Hua Wang; Pengfei Li; Xinke Zhang; Zhongjun Xia; Yue Lu; Huiqiang Huang
Journal:  Oncol Lett       Date:  2016-06-09       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.